OOIR: Observatory of International Research

Papers

(The H4-Index of Leukemia is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	2256
STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem/progenitor cells	1984
Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia	176
CD38 in the pathobiology of cutaneous T-cell lymphoma and the potential for combination therapeutic intervention	169
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia	154
Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415	140
TLE4 is a repressor of the oncogenic activity of TLX3 in T-cell acute lymphoblastic leukemia	135
Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action	122
Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study	122
Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance	120
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia	120
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma	117
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia	99
Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma	98
Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database	93
Inhibition of NOTCH4 sensitizes FLT3/ITD acute myeloid leukemia cells to FLT3 tyrosine kinase inhibition	91
Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia	90
Changing causes of death in persons with haematological cancers 1975–2016	88
Space exploration and cancer: the risks of deeper space adventures	88
Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms	84
Adding eltrombopag to intensive immunosuppressive therapy for severe aplastic anaemia may help adult patients achieve outcomes similar to paediatric patients	80
Measurable residual disease in haematological and solid cancers	80
Dimethyl fumarate ameliorates chronic graft-versus-host disease by inhibiting Tfh differentiation via Nrf2	78
“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward?	75
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results	75

Characterization of leukemia progression in the Cbfb-MYH11 knockin mice by single cell RNA sequencing	73
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures	73
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia	71
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	69
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	68
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)	68
Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection	68
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy	67
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients	66
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	65
Emil J. Freireich: Legend in Cancer Research (March 16, 1927 to February 1, 2021)	65
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome	63
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?	63
Fc-fused IL-7 mobilizes long-term HSCs in a pro-B cell-dependent manner and synergizes with G-CSF and AMD3100	62
Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis	61
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort	60
Why are haematopoietic stem cells in the bone marrow: ontology recapitulates phylogeny	59
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial	59
Perspectives on acute myeloid leukemia diagnosis: a comparative analysis of the latest World Health Organization and the International Consensus Classifications	59
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients	58
Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms	58
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial	56
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	54
Correction: Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15	53
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies	53
An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies	53
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods	52